Cambridge-based Editas gets $120M investment to advance genome editing

Kendall Square startup Editas Medicine, which aims to cure diseases by fixing disease-causing genes, today announced a $120 million investment, representing the second-largest venture capital rounds in Massachusetts so far this year.

The Series B round comes from more than a dozen public and private investors, some of which — like New York City-based Deerfield Management, which contributed $20 million, as well as Google Ventures— are traditionally known for technology, rather than biotech, financing. It comes on top of a $45 million Series A round announced in November 2013, when the company launched, and a deal with Seattle-based Juno Therapeutics in May that brought in $25 million up-front plus the potential for more than $700 million in coming years.